GB2561755A8 - Anti-placenta-chondroitin-sulfate chimeric antigen receptor and application thereof - Google Patents

Anti-placenta-chondroitin-sulfate chimeric antigen receptor and application thereof

Info

Publication number
GB2561755A8
GB2561755A8 GB1810451.3A GB201810451A GB2561755A8 GB 2561755 A8 GB2561755 A8 GB 2561755A8 GB 201810451 A GB201810451 A GB 201810451A GB 2561755 A8 GB2561755 A8 GB 2561755A8
Authority
GB
United Kingdom
Prior art keywords
antigen receptor
chimeric antigen
placenta
application
chondroitin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
GB1810451.3A
Other versions
GB2561755A (en
GB201810451D0 (en
Inventor
Yao Yongchao
Qi Hemei
Guo Wenzhong
Qin Li
Chen Xiaoping
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Guangzhou Cas Lamvac Biotech Co Ltd
Original Assignee
Guangzhou Cas Lamvac Biotech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CN201510843720.9A external-priority patent/CN105753991B/en
Priority claimed from CN201610032290.7A external-priority patent/CN106977607A/en
Application filed by Guangzhou Cas Lamvac Biotech Co Ltd filed Critical Guangzhou Cas Lamvac Biotech Co Ltd
Publication of GB201810451D0 publication Critical patent/GB201810451D0/en
Publication of GB2561755A publication Critical patent/GB2561755A/en
Publication of GB2561755A8 publication Critical patent/GB2561755A8/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C07K14/445—Plasmodium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001169—Tumor associated carbohydrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4631—Chimeric Antigen Receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4647—Protozoa antigens
    • A61K39/464714—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70532—B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

The present invention provides an anti-placenta chondroitin sulfate (pl-CS) chimeric antigen receptor and application thereof. The chimeric antigen receptor mainly comprises anti-pl-CS antigen recognition region, a hinge region, a transmembrane region and intracellular region, wherein the anti-pl-CS antigen recognition region is any one of a plasmodium protein VAR2CSA, a part of peptide segment of plasmodium protein VAR2CSA or a pl-CS antibody; and the part of peptide segment of the plasmodium protein VAR2CSA is a peptide segment with the number of amino acid greater than 500 in the plasmodium protein VAR2CSA.
GB1810451.3A 2015-11-26 2016-10-26 Anti-placenta-chondroitin-sulfate chimeric antigen receptor and application thereof Withdrawn GB2561755A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201510843720.9A CN105753991B (en) 2015-11-26 2015-11-26 Chimeric antigen receptor for resisting placenta-like chondroitin sulfate and application thereof
CN201610032290.7A CN106977607A (en) 2016-01-18 2016-01-18 A kind of Chimeric antigen receptor of anti-placenta sample chondroitin sulfate and its application
PCT/CN2016/103457 WO2017088623A1 (en) 2015-11-26 2016-10-26 Anti-placenta-chondroitin-sulfate chimeric antigen receptor and application thereof

Publications (3)

Publication Number Publication Date
GB201810451D0 GB201810451D0 (en) 2018-08-08
GB2561755A GB2561755A (en) 2018-10-24
GB2561755A8 true GB2561755A8 (en) 2018-12-12

Family

ID=58762879

Family Applications (1)

Application Number Title Priority Date Filing Date
GB1810451.3A Withdrawn GB2561755A (en) 2015-11-26 2016-10-26 Anti-placenta-chondroitin-sulfate chimeric antigen receptor and application thereof

Country Status (4)

Country Link
US (1) US20190153049A1 (en)
EP (1) EP3381946A4 (en)
GB (1) GB2561755A (en)
WO (1) WO2017088623A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110124045A (en) * 2019-04-30 2019-08-16 云南大学 Application of the plasmodium VAR2CSA albumen in anti-tumor drug

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11787844B2 (en) * 2012-02-09 2023-10-17 Var2 Pharmaceuticals Aps Targeting of chondroitin sulfate glycans
US9765342B2 (en) * 2012-04-11 2017-09-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric antigen receptors targeting B-cell maturation antigen
CN103589742A (en) * 2013-11-07 2014-02-19 申峰 Gene of intracellular domain of chimera antigen receptor and coding protein of gene
EP3262063B1 (en) * 2015-02-26 2021-09-22 Var2 Pharmaceuticals ApS Immunotherapeutic targeting of placental-like chondroitin sulfate using chimeric antigen receptors (cars) and immunotherapeutic targeting of cancer using cars with split-protein binding systems
CN104788573B (en) * 2015-05-08 2018-10-16 中国医学科学院血液病医院（血液学研究所） Chimeric antigen receptor hCD19scFv-CD8 α-CD28-CD3 ζ and application thereof

Also Published As

Publication number Publication date
EP3381946A1 (en) 2018-10-03
EP3381946A4 (en) 2019-08-07
US20190153049A1 (en) 2019-05-23
GB2561755A (en) 2018-10-24
WO2017088623A1 (en) 2017-06-01
GB201810451D0 (en) 2018-08-08

Similar Documents

Publication Publication Date Title
HK1257518A1 (en) Immune-stimulating humanized monoclonal antibodies against human interleukin-2, and fusion proteins thereof
PH12020551391A1 (en) Antibodies against signal-regulatory protein alpha and methods of use
EP3621642A4 (en) Human monoclonal antibodies against lag3 and uses thereof
GEP20237480B (en) Antibodies against signal-regulatory protein alpha and methods of use
EP3636761A4 (en) Antigen-binding protein recognizing mage-a4-derived peptide
MX2022001134A (en) Factor viii chimeric proteins and uses thereof.
IL279510A (en) Progranulin-fc polypeptide fusion proteins and uses thereof
AU2016219350A8 (en) Humanized anti-MUC1* antibodies
MX2019011952A (en) Anti-garp protein and uses thereof.
WO2018075820A3 (en) Cereblon-based heterodimerizable chimeric antigen receptors
IL276469A (en) Non-viral dna vectors and uses thereof for antibody and fusion protein production
EP3535294A4 (en) Anti-family with sequence similarity 19, member a5 antibodies and method of use thereof
EP3554544A4 (en) Anti-cub domain-containing protein 1 (cdcp1) antibodies, antibody drug conjugates, and methods of use thereof
EP3504244A4 (en) Macrophage stimulating protein receptor (or ron - recepteur d' origine nantais) antibodies and uses thereof
WO2015198243A3 (en) Compositions and methods for long acting proteins
PH12019501605A1 (en) Glucagon receptor binding proteins and methods of use thereof
IL268551B (en) Fgf21 mimetic antibodies and uses thereof
EP3790898A4 (en) Anti-family with sequence similarity 19, member a5 antibodies and method of use thereof
IL286216A (en) Tsg-6 antibodies and uses therefor
EA201992348A1 (en) ANTIGEN-BINDING PROTEINS INTERACTING WITH JAGGED1
GB2561755A8 (en) Anti-placenta-chondroitin-sulfate chimeric antigen receptor and application thereof
EP3917572A4 (en) Monoclonal antibodies against mhc-bound human dickkopf-1 peptides and uses thereof
AU2017305946A8 (en) C1q and HMGB1 fusion proteins and uses thereof
IL299757A (en) Sars-cov-2 proteins, anti-sars-cov-2 antibodies, and methods of using the same
IL285983A (en) Vectors and expression systems for producing recombinant proteins

Legal Events

Date Code Title Description
789A Request for publication of translation (sect. 89(a)/1977)

Ref document number: 2017088623

Country of ref document: WO

WAP Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1)